A Postdoctoral Fellow position with a bioinformatics/computational focus is available immediately in the laboratory of Dr. Brian J. O’Roak, Department of Molecular and Medical Genetics at Oregon Health & Science University (OHSU) for highly motivated individuals. There is an immediate need for a fellow with next-generation sequence analysis experience to lead a project exploring the role of germline mutations and somatic mosaicism in autism and other neurodevelopmental disorders (e.g. neural tube detects), for which funding currently exists—a SFARI funded project. Experience with whole-exome or genome sequencing required. Familiarity with statistics, population and gene databases, in silico predictive algorithms, structural variation tools, genetics and genomics is strongly preferred. Experience with RNA-seq and ChIP-seq is also preferred. Good communication skills are required.
OHSU is a highly collaborative environment. Fellows will have the opportunity to interact/collaborate with researchers from genetics, neurosciences, the new computational biology program, and clinical research programs focused on neurodevelopmental disorders. Moreover, OHSU has recently signed a unique collaborative agreement with Intel focused on developing the next-generation of computational approaches for human genetics; candidates with interest in this area of research are especially encouraged to apply.
The genetic intractability of complex genetic heterogeneous disorders, such as autism spectrum disorder (ASD), intellectual disability (ID), and broadly defined developmental delay, has been challenged in recent years; first by the application of genomewide platforms to detect copy number and more recently sequencing of the entire protein-coding genome (aka exome). Recent exome sequencing studies of families with simplex or “sporadic” ASD and ID has highlighted the importance of de novo mutations and led to the discovery of novel candidate genes. Moreover, genetic risk has been now shown to span what are generally considered distinct clinical disorders.
Highlights of Dr. O’Roak’s past research successes include: pioneering trio-based exome sequencing in simplex autism and developing new technologies for rapid and economical targeted resequencing. We are building on this experience by forming a strong and diverse research group focused on developing and implementing cutting-edge methods and technologies for discovery and replication, molecular diagnosis, functional dissection of pathways, and targeted therapeutics for neurodevelopmental and related disorders. This work has the potential to dramatically improve the lives of individuals affected with these currently untreatable disorders through early intervention and biologically based personal therapies.